USP22 and cancer: Our group is currently evaluating the preclinical efficacy of the first USP22-specific small molecule inhibitor in overcoming the ICB immunotherapeutic resistance for the treatment of a broad spectrum of solid tumors and conducting IND, enabling studies to translate a USP22-specific inhibitor from bench to bedside to treat human cancers.